Search this website. You can use fund codes to locate specific funds

Tackling post-pandemic pharmaceutical challenges

A panel debate on the role of companies and investors

Last month we looked at post-pandemic pharmaceutical challenges as part of a panel session we hosted for the US Council of Institutional Investors (CII) virtual Spring 2021 conference.

Moderated by Katie Frame, our other engagers Dr Emma Berntman and Sarah Swartz were joined by Damiano de Felice, director of strategy at the Access to Medicine Foundation and Silas Holland, head of communications and external affairs at the AMR Action Fund.

The pandemic has highlighted the vulnerability of our healthcare systems and inequities in access to them. So we asked what can companies and investors do to mitigate these issues? What did we learn along the way in the race for the vaccine? And what has the pandemic shown in terms of links between the sustainability agenda and human health?

We take a global approach to engagement with companies so our panel applied an international lens to looking at these challenges, as well as wider issues such as antimicrobial resistance and equitable vaccine distribution. Inviting questions from the audience, make sure you catch up with this session to hear why companies and investors need to step up to tackle pharmaceutical challenges in a post-pandemic world.

Watch the recording in full below or click to jump to a section.

Opening remarks – 01:33

Stimulating greater investment into R&D – 26:58

Beyond Pharma – other actors tackling AMR – 33:32

Contributors of AMR – 42:06

Equitable vaccine distribution – 51:01

Closing remarks – 57:32

Related Insights

ExxonMobil case study
Climate change is a material issue for ExxonMobil, which is the largest emitter in the US and the fifth largest emitter globally.
Samsonite case study
Samsonite has launched a sustainability strategy to 2030, including plans to use 100% renewable energy and achieve operational carbon neutrality by 2025.
Battling the superbugs
Misuse and overuse of antibiotics within industrial animal farming is recognised as a leading cause of the rise in AMR.
Playing catch up – the challenge for Japan
How are we engaging with Japanese companies and policymakers to accelerate the energy transition and support women in the workplace?
BP case study
BP has committed to become net-zero by 2050 or sooner, supported by a robust strategy to get there and market-leading disclosures.
Institutional investors believe ESG factors are more important than financial metrics when evaluating a company’s long-term attractiveness
ESG factors have grown in importance to institutional investors, according to a survey of 100 UK-based institutional investors by Federated Hermes, a global leader in active, responsible investing.

EOS Client Service and Business Development

Amy D’Eugenio,
Head of Client Service and Business Development, EOS